Free Download

Dupilumab reduces systemic corticosteroid use and sinonasal surgery rate in CRSwNP

Volume: 59 - Issue: 3

First page: 301 - Last page: 311

M. Desrosiers - L.P. Mannent - N. Amin - G.W. Canonica - P.W. Hellings - P. Gevaert - J. Mullol - S.E. Lee - S. Fujieda - J.K. Han - C. Hopkins - W. Fokkens - R. Jankowski - S.H. Cho - X. Mao - M. Zhang - M.S. Rice - A.H. Khan - S. Kamat - N. Patel - N.M.H. Graham - M. Ruddy - C. Bachert

BACKGROUND: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a type 2 inflammatory disease with a high symptom burden and poor quality of life. Treatment options include recurrent surgeries and/or frequent systemic corticosteroids (SCS). Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukin-4 and interleukin-13, key drivers of type 2-mediated inflammation. We report results of pooled analyses from 2 randomised, double-blind, placebo-controlled phase 3 studies (SINUS 24 [NCT02912468]; SINUS-52 [NCT02898454]) to evaluate dupilumab effect versus placebo in adults with CRSwNP with/without SCS use and sinonasal surgery.
METHODOLOGY: SINUS-24 patients were randomised 1:1 to subcutaneous dupilumab 300 mg (n=143) or placebo (n=133) every 2 weeks (q2w) for 24 weeks. SINUS-52 patients were randomised 1:1:1 to 52 weeks of subcutaneous dupilumab 300 mg q2w (n=150), 24 weeks q2w followed by 28 weeks of dupilumab 300 mg every 4 weeks (n=145) or 52 weeks of placebo q2w (n=153).
RESULTS: Dupilumab reduced the number of patients undergoing sinonasal surgery (82.6%), the need for in-study SCS use (73.9%), and SCS courses (75.3%). Significant improvements were observed with dupilumab vs placebo regardless of prior sinonasal surgery or SCS use in nasal polyp, nasal congestion, Lund-MacKay, and Sinonasal Outcome Test (22-items) scores, and the University of Pennsylvania Smell Identification Test.
CONCLUSIONS: Dupilumab demonstrated significant improvements in disease signs and symptoms and reduced the need for sino-nasal surgery and SCS use versus placebo in patients with severe CRSwNP, regardless of SCS use in the previous 2 years, or prior sinonasal surgery.

Rhinology 59-3: 301-311, 2021

To see the issue content and the abstract you do not have to login

Please login to download the full articles

If you do not have a subscription to Rhinology please consider taking one.

Click here to become a member of the European Rhinologic Society and a subscriber to the journal `RHINOLOGY`, from 2022. Subscription including membership fee: Euro 135.-

  1. Slot Online
  2. Situs Judi Slot Online Terbaik Indonesia
  3. Situs Judi Slot Online
  4. Daftar Situs Judi Slot Online Terpercaya
  5. Situs Judi Slot Online Terpercaya 2021
  6. Daftar Slot Online
  7. Judi Slot Online Jackpot Terbesar
  8. Judi Slot Online
  9. Agen Slot Online
  10. Game Slot Online
  11. Slot Online Indonesia
  12. Slot Online Terbaik
  13. Judi Slot Online Terpercaya
  14. Slot Online Yang Sering Kasih Jackpot
  15. Slot Online Terbaru
  16. Judi Slot
  17. Slot Gacor